Abstract
The withdrawal of the celebrity arthritis drug, rofecoxib (Vioxx) has sparked an intense discussion and controversy about the safety of the selective COX-2 inhibitors. Laboratory, epidemiological, and clinical studies have surged and continued to evaluate and understand the safety of coxibs and traditional NSAIDs. This paper reviews the scientific and clinical basis of not only the risks, but also the benefits surrounding the use COX-2 inhibitors and NSAIDs. Discussion, debate, opinions, regulatory and clinical recommendations have evolved since the unexpected emergence of cardiac thrombotic events from the use of these drugs. The evidence by which coxibs and NSAIDs can potentially attenuate or exacerbate cardiovascular disease by affecting endothelial function is assessed; and how NSAIDs and coxibs affect renal function and blood pressure is revisited. Several investigations provide insight into their mechanism and clinical application.
Keywords: COX-2 inhibition, COX-blockade, NSAIDs, coxibs, COX-2 selective inhibitor, COX-2 specific inhibitor, endothelial dysfunction, gastrointestinal toxicity
Current Drug Safety
Title: Risk-Benefit Perspectives in COX-2 Blockade
Volume: 3 Issue: 1
Author(s): Susan Dabu-Bondoc and Samantha Franco
Affiliation:
Keywords: COX-2 inhibition, COX-blockade, NSAIDs, coxibs, COX-2 selective inhibitor, COX-2 specific inhibitor, endothelial dysfunction, gastrointestinal toxicity
Abstract: The withdrawal of the celebrity arthritis drug, rofecoxib (Vioxx) has sparked an intense discussion and controversy about the safety of the selective COX-2 inhibitors. Laboratory, epidemiological, and clinical studies have surged and continued to evaluate and understand the safety of coxibs and traditional NSAIDs. This paper reviews the scientific and clinical basis of not only the risks, but also the benefits surrounding the use COX-2 inhibitors and NSAIDs. Discussion, debate, opinions, regulatory and clinical recommendations have evolved since the unexpected emergence of cardiac thrombotic events from the use of these drugs. The evidence by which coxibs and NSAIDs can potentially attenuate or exacerbate cardiovascular disease by affecting endothelial function is assessed; and how NSAIDs and coxibs affect renal function and blood pressure is revisited. Several investigations provide insight into their mechanism and clinical application.
Export Options
About this article
Cite this article as:
Dabu-Bondoc Susan and Franco Samantha, Risk-Benefit Perspectives in COX-2 Blockade, Current Drug Safety 2008; 3 (1) . https://dx.doi.org/10.2174/157488608783333970
DOI https://dx.doi.org/10.2174/157488608783333970 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Steerable Sheath Technology in the Ablation of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Assessment of Cardiac Performance with Magnetic Resonance Imaging
Current Cardiology Reviews Integrin Signaling Networks in the Pathobiology of Vascular Smooth Muscle Cells
Vascular Disease Prevention (Discontinued) Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins
Current Pharmaceutical Design Benefits of Olive Oil Phenolic Compounds in Disease Prevention
Endocrine, Metabolic & Immune Disorders - Drug Targets Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Cytotoxic and Apoptotic Effect of <i>Iris taochia</i> Plant Extracts on Human Breast Cancer (MCF-7) Cells
Current Proteomics Macrophages: Promising Targets for the Treatment of Atherosclerosis
Current Vascular Pharmacology Protective Effects of Pomegranate in Endothelial Dysfunction
Current Pharmaceutical Design Role of Antioxidants in Redox Regulation of Diabetic Cardiovascular Complications
Current Pharmaceutical Biotechnology Comparative Studies of the Antioxidant Effects of Cis- and Trans- Resveratrol
Current Medicinal Chemistry Potential Options to Treat Hypertriglyceridaemia
Current Drug Targets Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Synthesis and Antihypertensive Activity of Novel Quinazolin-4(3H)-one Derivatives
Central Nervous System Agents in Medicinal Chemistry Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition Xanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry